Galectin Therapeutics Inc.
GALT
$4.05
-$0.09-2.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -21.17% | 47.61% | 54.04% | 27.06% | 39.20% |
| Total Depreciation and Amortization | 100.00% | 20.00% | 310.00% | -100.00% | -77.78% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 119.90% | -116.79% | 151.55% | 86.92% | 121.27% |
| Change in Net Operating Assets | 332.78% | 19.87% | -462.27% | 55.08% | -132.63% |
| Cash from Operations | 63.06% | 49.72% | 52.76% | 58.51% | 20.77% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | 10.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.77% | -- | 162.87% | -- | 416.49% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -87.66% | -- | 1,337.96% | -87.04% | 24.73% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -113.28% | 53.06% | 151.88% | -253.63% | 210.33% |